Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of breakeven. This compares to a loss of $0.06 per share a year ago. These figures are ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025.

Before you buy stock in Gilead Sciences, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gilead ...

The company best known for its Cologuard colon cancer screening test posted a loss of $86 million, or $0.45 per share, on revenue of $878.4 million.

Joel Mokyr, Philippe Aghion and Peter Howitt have been awarded the 2025 Nobel Prize in Economics. (Photo by Jonathan Nackstrand / AFP) / ALTERNATIVE CROP (Photo by JONATHAN NACKSTRAND/AFP via Getty ...

Oracle announced the Oracle Life Sciences AI Data Platform, a generative AI-enabled solution designed to empower pharmaceutical, medical device, research, and life sciences organizations to accelerate ...

Anavex Life Sciences (AVXL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.